# BPC-157 FAQ — Questions About Legitimacy, Regulatory Status, and the Research Record > Frequently asked questions about BPC-157: Is it legitimate? What did the FDA do? Is WADA prohibition real? Has it been tested in humans? Answered from the peer-reviewed literature and regulatory record. ## Research and Science **Is BPC-157 a legitimate research compound with peer-reviewed studies behind it?** Yes, with an important qualification. BPC-157 (sequence GEPPPGKPADDAGLV, MW 1419.5 Da) has an established molecular identity and a substantial body of peer-reviewed animal research published in indexed journals [1][2][3]. A 2025 HSS Journal systematic review identified 544 published BPC-157 articles from 1993 to 2024, with 36 focused on orthopaedic outcomes alone [16]. The findings across musculoskeletal, GI, and neurological rodent models are consistently favorable. What it is not is a legitimate therapeutic in the regulatory sense: only three small human pilot studies have been published, the one Phase II human trial in ulcerative colitis was never published in peer-reviewed form [8], and no regulatory authority has approved BPC-157 for any human indication. **What does the published research actually show about BPC-157's mechanism of action?** BPC-157 engages multiple overlapping signaling cascades rather than a single molecular target [8]. The most studied are: (1) VEGFR2/Akt-eNOS activation, promoting angiogenesis and vascular repair [3]; (2) FAK-paxillin signaling, driving fibroblast migration during tissue repair [8]; (3) JAK2/STAT signaling via growth hormone receptor upregulation — in tendon fibroblasts, BPC-157 produced approximately a 7-fold increase in GHR expression at day 3, amplifying downstream growth-promoting signals when co-applied with exogenous GH [2]; and (4) ERK1/2 activation supporting cell proliferation [8]. It also modulates nitric oxide synthesis in an adaptive, context-dependent manner and normalizes dopaminergic and serotonergic function in CNS perturbation models [9]. **What is the half-life and pharmacokinetic profile of BPC-157 based on animal studies?** A 2022 Frontiers in Pharmacology study directly characterized BPC-157 ADME in rats and beagle dogs [13]. Key parameters: IV elimination half-life under 30 minutes in both species; intramuscular bioavailability 14–19% in rats and 45–50% in dogs; peak tissue concentrations in kidney and liver within 3 minutes of IV dosing; elimination primarily via urine and bile; metabolism to constituent amino acids. No human pharmacokinetic data exist [13]. **Has BPC-157 ever been tested in human clinical trials, and what were the results?** Three published human pilot studies exist as of early 2025 [15]. First, a 2003 Phase I safety study in healthy volunteers demonstrated that BPC-157 was well-tolerated. Second, a Phase II multicenter RCT designated PL 14736 was conducted for mild-to-moderate ulcerative colitis; the trial was completed, but full results were never published as a peer-reviewed paper [8] — making independent evaluation impossible. Third, one published human clinical study examined intra-articular knee injection in 12 patients with chronic pain, with 7 out of 12 reporting relief lasting more than 6 months [15]. No major adverse events were reported across the three pilots, but sample sizes ranged from n=2 to n=16. **What are the most significant limitations of the BPC-157 research body to date?** Five limitations are regularly cited [15][16][17]: (1) Nearly all published studies originate from a single research group at the University of Zagreb; independent replication is limited. (2) Human evidence consists of three small pilot studies; no adequately powered RCT has been published. (3) The Phase II PL 14736 trial was completed but never published in peer-reviewed form. (4) No human pharmacokinetic data exist; species-to-species bioavailability varies substantially. (5) Long-term safety is poorly characterized in any species. **How do I verify that a BPC-157 product contains the correct peptide sequence?** The canonical BPC-157 amino acid sequence is GEPPPGKPADDAGLV — 15 residues with four proline positions [1][17]. Verification requires HPLC to assess purity and confirm the correct molecular weight (~1419.5 Da), and mass spectrometry to confirm the peptide sequence. Because BPC-157 exists outside any regulatory quality framework [15], no standardized quality assurance process applies to commercially available research-grade products. ## Regulatory Status **What is the regulatory status of BPC-157 — is it FDA approved, banned, or in a gray zone?** All three descriptions apply to different regulatory dimensions [15]. FDA-approved: No. FDA-banned from compounding: Yes — Category 2 bulk drug substance since September 2023. DEA-scheduled: No — possession is not federally criminalized. WADA-prohibited: Yes — listed under S0 since 2022, banned at all times. EMA/MHRA approved: No. No active IND in the US. **Why did the FDA prohibit BPC-157 from compounding pharmacies in 2023?** The FDA's Category 2 designation cites three stated concerns [15]: insufficient human safety data, potential for immune reactions, and manufacturing impurity concerns. Category 2 is a prohibition, not a needs-more-review status. **What does WADA say about BPC-157, and can athletes get a Therapeutic Use Exemption?** WADA lists BPC-157 under Section S0 — Non-Approved Substances [15]. S0 applies both in-competition and out-of-competition. A TUE for BPC-157 is not available: TUEs require the compound have at least one approved therapeutic indication. USADA has specifically noted that no safe dose has been established in humans. **Is BPC-157 a scheduled controlled substance, and is it legal to possess in the US?** BPC-157 is not scheduled under the Controlled Substances Act and is not a DEA-controlled substance as of 2025 [15]. Possession in the United States is not federally criminalized. However, sale as a drug, food, or dietary supplement without FDA approval is unlawful under federal law. **What happened to the Phase II PL 14736 ulcerative colitis trial results?** A Phase II multicenter, randomized, double-blind, placebo-controlled study was completed in patients with mild-to-moderate ulcerative colitis [8]. Phase I in healthy volunteers demonstrated tolerability. The Phase II study was completed, with reports indicating efficacy and no toxicity. However, the full dataset was never published as a standalone peer-reviewed paper [8], preventing independent evaluation. **What is the significance of BPC-157 research being concentrated in one research group?** The large majority of BPC-157's published literature originates from the research group of Predrag Sikiric and Sven Seiwerth at the University of Zagreb [15][16]. Findings from a single research group represent a weaker evidence base than findings independently replicated by multiple teams. Both the 2025 HSS Journal systematic review and the 2025 Current Reviews in Musculoskeletal Medicine narrative review note this as a significant limitation. **Has any other regulatory authority besides the FDA taken action on BPC-157?** WADA's S0 prohibition (2022) is the most significant non-FDA regulatory action [15]. No EMA, MHRA, or TGA approval exists for any BPC-157 indication. No international body — including WHO — has issued an INN for BPC-157. ## Compound Identity and Sourcing **Is BPC-157 a naturally occurring compound in the human body?** Partially. BPC-157 is a synthetic peptide whose sequence corresponds to a partial sequence of a protein found in human gastric juice [1][17]. The parent protein is present in the human body; the 15-amino acid fragment BPC-157 is not known to circulate in blood at measurable concentrations. The compound as administered in research is a synthetic product, not an extract [17]. **What is BPC-157's legal classification in the US as of 2025?** BPC-157 in the US as of 2025 [15]: (1) Not an FDA-approved drug. (2) Category 2 bulk drug substance under 503A and 503B — licensed compounding pharmacies may not produce it. (3) Not a DEA Controlled Substance. (4) A WADA-prohibited substance (S0). (5) Sale as a drug, food, or dietary supplement is unlawful without FDA approval. ## References [1] Krivic A, et al. Achilles detachment and BPC 157. Journal of Orthopaedic Research. 2006. DOI: 10.1002/jor.20096. PMID: 16583442. [2] Chang CH, et al. BPC 157 Enhances GHR Expression. Molecules. 2014. DOI: 10.3390/molecules191119066. PMID: 25415472. [3] Brcic L, et al. Modulatory effect of BPC 157 on angiogenesis. Journal of Physiology and Pharmacology. 2009. PMID: 20388964. [8] Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for IBD. Inflammopharmacology. 2006. DOI: 10.1007/s10787-006-1531-7. PMID: 17186181. [9] Sikiric P, et al. Brain-gut Axis and BPC 157. Current Neuropharmacology. 2016. DOI: 10.2174/1570159x13666160502153022. PMID: 27138887. [13] He L, et al. Pharmacokinetics of BPC 157 in rats and dogs. Frontiers in Pharmacology. 2022. DOI: 10.3389/fphar.2022.1026182. PMID: 36588717. [15] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157. Current Reviews in Musculoskeletal Medicine. 2025. DOI: 10.1007/s12178-025-09990-7. PMID: 40789979. [16] Yuan C, et al. From Regeneration to Analgesia: The Role of BPC-157. International Journal of Molecular Sciences. 2026. DOI: 10.3390/ijms27062876. PMID: 41898733. [17] Concerning BPC-157, a natural pentadecapeptide. Inflammopharmacology. 2025. DOI: 10.1007/s10787-025-01882-z. PMID: 40759852. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.